Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Creating evidence to tackle COVID-19

Our COVID-19 reading template is in use for two weeks, and its usage is multiplying. We are grateful for the close cooperation and feedback from existing and new mint Lesion™ users.

Our medical team went through all the available publications and created a reading template that can be used with ease by readers in your hospital or research center. As new papers and guidelines become available, we will update the reading template, retaining the structured data already collected.

mint Lesion™ extracts all primary data - including radiomics features - from images, and immediately links any measured value to its context and further related data of clinical significance. Together with clinical endpoints, the mineable data is ready for real-time analytics and AI.

Let mint Lesion™ assist you in generating the data and creating the evidence that will enable us to tackle COVID-19 jointly.

Request a demo

Related Resources

Related Resources

Several juxtaposed images of different patients with different responses to the cancer treatment

Study with mint Lesion™ compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study conducted by researchers at University Hospital Tuebingen retrospectively compared two liver-targeted therapies for uveal melanoma patients…

RECIST measurements of a patient with uveal melanoma and hepatic metastases

University Hospital Tuebingen: Study compares the Efficacy of SIRT and CS-PHP in Uveal Melanoma with Hepatic Metastasis

A study[1] conducted by researchers at University Hospital Tuebingen retrospectively compared the efficacy of two liver-targeted therapies,…

Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

University Hospital Munich (LMU): Study Analyzing the Tumor Growth Rate as a Prognostic Biomarker in Lymphoma Patients Under CAR T-Cell Therapy

A recent study[1] conducted by researchers at the University Hospital Munich (LMU) investigated the role of tumor growth rate (TGR) in predicting the…